<?xml version="1.0" encoding="utf-8"?>
<items><story><date>08:24 03 January 2007 (UTC)</date><text>Jan 3 Poniard Pharmaceuticals Inc. PARD.O
said it received a special protocol assessment from the U.S.
Food and Drug Administration for its pivotal late-stage trial
of picoplatin for the treatment of small cell lung cancer. In a statement, the pharmaceutical company said it plans to
begin a pivotal Phase III study of picoplatin efficacy after
relapse in the first half of 2007.
 (Reporting by Dilipp S. Nag in Bangalore)


</text><link>http://www.reuters.com/article/2007/01/03/poniard-fda-idUSWNAS659220070103</link><sectors><value><value>Regulatory News</value></value></sectors><title>poniard pharma gets special protocol ok for late - stage trial</title></story></items>